Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition.
27 August 2018 (14:00 - 18:00)
Organised by:
Abstract
Slides
About the speaker
University Medical Center Utrecht, Utrecht (Netherlands (The))
4 More presentations in this session
Access the full session
The Event
ESC Congress 2018
27 August 2018
14:00 CET
